Analysis

Mbx Biosciences, Inc. (MBX) Stock Analysis

Mbx Biosciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to MBX.

websiteMBX/analysis/MBX

Mbx Biosciences, Inc.

Mbx Biosciences, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to MBX.

Stock profile

Ticker

MBX

Asset type

Stock

Market cap

$2.05B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Mbx Biosciences, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • MBX primary listing

Latest Mbx Biosciences, Inc. news

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Thera...

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activit...

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerc...

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, de...

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, de...

Research sections

Valuation

Review valuation context for Mbx Biosciences, Inc..

Future growth

Review future growth context for Mbx Biosciences, Inc..

Past performance

Review past performance context for Mbx Biosciences, Inc..

Financial health

Review financial health context for Mbx Biosciences, Inc..

Dividend

Review dividend context for Mbx Biosciences, Inc..

Management

Review management context for Mbx Biosciences, Inc..

Ownership

Review ownership context for Mbx Biosciences, Inc..

Other information

Review other information context for Mbx Biosciences, Inc..

Community

Review community context for Mbx Biosciences, Inc..